Eyam Health

What Eyam Health does

Eyam Health is a late preclinical-stage biotechnology company founded in 2020 in Vancouver, BC, built on the Gemini self-amplifying DNA (saDNA) and RNA (saRNA) platform originally invented at the University of British Columbia. The platform enables sustained, in vivo expression of therapeutic proteins for six or more months from a single, carrier-free intramuscular dose — eliminating the need for lipid nanoparticles or viral vectors that currently limit dosing duration and redosability in genetic medicine. Gemini comes in two variants — Gemini-D (saDNA) for long-acting therapeutics and Gemini-R (saRNA) for vaccine applications — and supports multi-payload constructs of up to five open reading frames. Paired with the platform is Jennerator, an in-house AI-driven immunoinformatics engine for vector-aware payload design, epitope prediction, and HLA/MHC optimization.

The company monetizes through a B2B partnership model offering feasibility studies, by-indication or by-geography platform licenses with tiered royalties, joint co-development arrangements, and product licensing of de-risked IND-directed assets. Customer segments include pharmaceutical and biotech companies seeking differentiated delivery platforms, global health organizations (Medicines for Malaria Venture, Bill & Melinda Gates Foundation) targeting low- and middle-income countries, and animal health companies. Eyam also pursues grant funding through global health and government programs.

Eyam is currently generating early revenue, closing its first commercial agreement in 2025, and has secured validation through peer-reviewed publication in Nature Communications. The company graduated from Creative Destruction Lab in 2026, holds 18 platform patents, is led by Founder/CSO Dr. Wilfred Jefferies and CEO Ryan Thomas, and is actively pursuing a Series A round.

Name

Eyam Health

Legal name

Eyam Vaccines and Immunotherapeutics

Website

https://eyamhealth.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Eyam Health is a Vancouver-based preclinical biotech developing Gemini, a carrier-free self-amplifying DNA/RNA delivery platform paired with Jennerator AI for payload design, enabling six-month therapeutic protein expression from a single dose. It licenses the platform to pharma, global health, and animal health partners.

Ownership category

akta.pro rank

Product category

Genetic Medicine Delivery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAIAD

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAIAI

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAAAH

Therapeutic Peptides & Protein/Peptide Biologics

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

SECONDARYHLAAAIAB

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Self-amplifying DNA delivery
• Nucleic acid therapeutics
• Vaccine delivery platform
• Immunoinformatics AI
• Genetic medicine platform

Headquarters

HQ city

Surrey

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Platform licensing (tiered royalties): License fees and tiered royalty payments from pharmaceutical and biotech partners applying the Gemini platform to specific therapeutic areas or geographies. By-indication or by-geography licensing structures.
2. Feasibility study fees: Milestone-gated payments from feasibility studies structured as MTA or non-commercial licensing agreements. Eyam runs assays; partner evaluates Gemini against proprietary programs. Payments tied to milestones.
3. Co-development R&D funding: Joint R&D arrangements combining partner clinical/regulatory capabilities with Gemini delivery. Partner co-funds development in exchange for preferred commercial terms.
4. Product licensing (IND-directed): In-licensing of de-risked IND-directed programs (e.g., CaV1.4 oncology). Eyam licenses pre-validated assets for further development.
5. Commercial agreements: First commercial agreement for a Gemini-based biologic was closed in 2025, marking transition from research-stage to revenue-generating biotech.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Eyam Health develops the Gemini self-amplifying DNA/RNA delivery platform and the Jennerator AI immunoinformatics engine to design and deliver genetic medicines. Gemini produces months of therapeutic protein from a single, non-viral, thermostable intramuscular dose without lipid nanoparticles or viral vectors, while Jennerator optimizes payloads for expression and durability. The company licenses these platforms to pharmaceutical, biotech, global health, and animal health partners through feasibility studies, platform licenses, co-development agreements, and product licensing.

Product overview

Eyam Health offers two integrated platform technologies: the Gemini platform, a self-amplifying DNA/RNA delivery system that programs the body to produce therapeutic proteins for months from a single dose, and the Jennerator AI platform that designs and optimizes genetic payloads for maximum expression and durability. Gemini comes in two variants—Gemini-D (saDNA for 6+ month expression) and Gemini-R (saRNA for ~42-day expression)—both enabling non-viral, carrier-free, room-temperature-stable delivery without lipid nanoparticles or viral vectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Gemini Platform Self-amplifying DNA (saDNA) and self-amplifying RNA (saRNA) delivery platform that enables sustained production of therapeutic proteins in the body for months from a single, non-viral, room-temperature-stable dose without lipid nanoparticles or viral vectors. Licensed to pharmaceutical, biotech, global health, and animal health partners via feasibility studies, by-indication or by-geography platform licenses, and co-development agreements.
• Jennerator AI Platform AI-driven immunoinformatics engine that designs and optimizes genetic payloads for the Gemini delivery platform. Predicts epitopes, optimizes HLA/MHC binding, and tunes payloads for expression and durability. Incorporates vector-aware design that considers delivery mechanisms during drug design to de-risk clinical translation. Used in-house by Eyam and combined with Gemini licenses for partner programs.
• Gemini-D (saDNA variant) Self-amplifying DNA (saDNA) construct enabling 6+ months of therapeutic protein expression from a single, carrier-free intramuscular dose. Designed for single-dose long-acting therapeutics with integration below FDA limits. Does not require lipid nanoparticles or viral capsids, enabling redosing.
• Gemini-R (saRNA variant) Self-amplifying RNA (saRNA) construct enabling approximately 42-day expression, ideal for prime-boost vaccination and vaccine applications. Zero genomic integration. Uses the same carrier-free, non-viral delivery architecture as Gemini-D.

Quantifiable outcome

• Sustained antibody expression above therapeutic threshold (~10 µg/mL) through Day 189 (6 months) from a single dose
• +6 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered supporting, strategic and core.

• Creative Destruction Lab (CDL)supportingOthers · 11 June 2026Eyam was accepted into and graduated from the CDL Vancouver Biomedical stream — one of the world's leading science-driven accelerators. Over nine months, Eyam validated its Gemini platform in two large-animal species, grew its pharma partner roster, and defined its clinical build strategy. CDL ventures have collectively generated over CAD $55 billion in equity value.
• iiDiagnostics / Infection Innovation Consortium (iiCON)strategicStrategic or Co-development Partner · 15 January 2026£750,000 UK-Canada collaboration combining Eyam's Gemini and Jennerator platforms with LSTM's automated organoid technology through iiDiagnostics. First commercial project in the Liverpool Robotic Infection Research Laboratory (one of the first Category Three Level robotic labs in the UK). NRC IRAP providing advisory services and up to $455,000 CAD in funding. Focus on universal SARS-CoV-2 vaccine candidate and multi-antigen payload validation.
• Liverpool School of Tropical Medicine (LSTM)strategicStrategic or Co-development Partner · 15 January 2026LSTM provides advanced organoid automation and containment research capabilities through the Liverpool Robotic Infection Research Laboratory for co-development of Eyam's saDNA-based vaccine candidates. Leading the development of the first physiologically relevant, automated tonsillar organoid model for high-fidelity vaccine testing.
• Medicines for Malaria Venture (MMV)coreStrategic or Co-development Partner · 21 July 2025Eyam and MMV entered a strategic research partnership to develop next-generation monoclonal antibody-based antimalarials using Gemini and Jennerator platforms. The partnership aims to create affordable, long-lasting preventive therapies for malaria — targeting <$1 per dose — for children and pregnant women in sub-Saharan Africa. Gemini can carry multiple antibodies at once in a single dose, targeting multiple stages of the parasite lifecycle.
• Top 5 Animal Health Company (partner undisclosed)coreStrategic or Co-development Partner · 18 July 2025Advancing a joint development program focused on antibody-based therapeutics for chronic conditions in companion animals. The collaboration entered its next phase in 2025, evaluating performance and tolerability in a canine model with the goal of moving the target into clinical trials. Eyam's Gemini platform enables durable, low-dose therapeutic expression without lipid nanoparticles, addressing a scalable solution for both veterinary and human health applications.
• Pirbright Institute (UK)supportingTechnology or Integration · 1 January 2025NHP studies for Gemini platform validation underway at Pirbright Institute in the UK. Pig study successfully completed at Pirbright in 2025, proving construct stability and transfection capacity at scale in a physiological environment closer to humans.
• Tulane University (USA)supportingTechnology or Integration · 1 January 2025Non-human primate (NHP) studies for Gemini antibody expression durability underway at Tulane University (USA), complementing studies at Pirbright Institute.
• MitacssupportingStrategic or Co-development Partner · 31 May 2023Partnership with Mitacs (national not-for-profit empowering innovation) to establish Eyam's Sentinel AI: Office of Pandemic Preparedness research facility. The facility is dedicated to AI-informed smart vectors, next-generation vaccines, therapeutics, and Jennerator platform development. Mitacs supports post-doctoral scientific research and drives economic growth through the partnership.
• University of British Columbia (UBC)coreTechnology or Integration · 1 January 2020Gemini platform invented at UBC by Dr. Wilfred Jefferies. Eyam holds an option to exclusively license CaV1.4 antibody patents for leukemia and lymphoma from UBC. Dr. Jefferies is a professor at UBC and serves as Eyam's Chief Scientific Officer and Founder. Eyam was built on the Gemini platform invented at UBC.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• BioNTech: BioNTech pairs mRNA-LNP delivery with a broad oncology and infectious-disease pipeline and is a primary competitor in the genetic-medicine delivery space. Its FixVac and individualized neoantigen programs overlap with Eyam's vaccine and oncology ambitions.
• Translate Bio (Sanofi): Translate Bio, acquired by Sanofi, developed an mRNA therapeutics platform for vaccines and protein-replacement diseases. It represents a larger-scale mRNA delivery incumbent whose pipeline overlaps with Eyam's therapeutic-protein-expression ambitions.
• Intellia Therapeutics: Intellia is a clinical-stage CRISPR/Cas9 gene-editing company with both in vivo and ex vivo programs. It is a broad incumbent in in vivo nucleic-acid therapeutics and shares Eyam's ambition of durable, single-administration genetic medicines.
• Moderna: Moderna is the leading mRNA-LNP platform company with commercial vaccines and a broad therapeutic pipeline. It is the dominant incumbent in nucleic-acid delivery and defines the cost/immunogenicity benchmarks Eyam's carrier-free platform must beat.
• Verve Therapeutics: Verve is developing in vivo base-editing therapies delivered via LNPs for cardiovascular disease. It is comparable to Eyam as a nucleic-acid-delivery platform company targeting therapeutic protein expression / editing in vivo from a single dose.

Emerging players

• Nutcracker Therapeutics: Nutcracker is an early-stage company building an integrated microfluidic biochip-based platform for on-demand mRNA therapeutics manufacturing. It overlaps with Eyam in nucleic-acid therapeutics delivery, though with a manufacturing-focused technology angle.
• Touchlight Genetics: Touchlight produces enzymatic (cell-free) DNA for genetic medicines and vaccines, including dbDNA and proDNA. It is an enabling/synthetic-biology peer whose DNA manufacturing technology addresses the same upstream supply chain Eyam's plasmid DNA delivery depends on.

Direct peers

• Arcturus Therapeutics: Arcturus develops self-amplifying mRNA (saRNA) vaccines and therapeutics using an LNP delivery platform. It is the closest publicly-traded comparator to Eyam's self-amplifying nucleic-acid approach, although Arcturus relies on LNPs while Eyam is carrier-free.
• Generation Bio: Generation Bio is developing non-viral, redosable DNA-based genetic medicines for rare diseases and other indications. Its cell-targeted lipid nanoparticle delivery shares Eyam's non-viral, redosable therapeutic ambition and similar target indication set.
• Strand Therapeutics: Strand is a preclinical-stage company engineering self-amplifying mRNA for programmable gene expression in immuno-oncology and other indications. Its self-amplifying mRNA platform directly overlaps Eyam's Gemini-R positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

• Xx.com/eyamhealth
• LinkedInlinkedin.com/company/eyamhealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyam Health